Introduction

Keythera (Suzhou) Biopharmaceuticals Co., Ltd.

Keythera, founded in 2020, is a clinical-stage biotech firm focused on pioneering small molecule drugs that effectively combat cancers and autoimmune disorders. The company's founder and core team members possess vast expertise in the field of drug discovery and development research. To build a robust portfolio of products, the company employs a strategy that leverages its affinity based high throughput screening technological platform. By doing so, the company aims to expedite the process of discovering and developing new drugs while also ensuring distinctiveness within its product pipelines.

100%

100% Bachelor or above
57%

57% Master degree
19%

19% Doctor degree
85.71%

R&D personnel

Vision

Our aim is to establish ourselves as a frontrunner in the field of discovering and developing groundbreaking small molecule drugs within China, while simultaneously becoming a pharmaceutical company with a global perspective and significant impact. Keythera Biopharmaceuticals is dedicated to uncovering and advancing small molecule therapies that specifically combat cancer and autoimmune disorders. By leveraging cutting-edge technologies and pioneering drug discovery, the company strives to address the wide-ranging gaps in medical treatment. Keythera Biopharmaceuticals' ultimate goal is to revolutionize healthcare by introducing innovative approaches and introducing groundbreaking medications.

Core values: Innovation & Integrity